This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given
together as a possible treatment for INI1-negative tumors.
This research study is a Phase II clinical trial, which tests the safety and effectiveness of
an investigational drug or drug combination to learn whether the drug or drug combination
works in treating a specific disease. "Investigational" means that the drug combination is
The names of the study drugs involved in this study are:
This trial is studying whether nivolumab and ipilimumab work to treat INI1-negative cancers.
The U.S. Food and Drug Administration (FDA) has not approved combination nivolumab and
ipilimumab for the specific diseases in this study but it has been approved for other
diseases. Nivolumab and ipilimumab have been tested in children to find out a safe dose of
Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney, Epithelioid Sarcoma, Chordoma (Poorly Differentiated or De-differentiated), Atypical Teratoid/Rhabdoid Tumor, Other INI1 Negative Malignant Tumors (With PI Approval)
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.